For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
4
views
0
references
 Top references
cited by
96
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
1 collections
    0
    shares
      0
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: not found

      Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Peripheral artery disease (PAD) is associated with heightened ischemic and bleeding risk in patients with prior myocardial infarction (MI).

          Related collections

          Author and article information

          Journal
          Journal ID (iso-abbrev): J. Am. Coll. Cardiol.
          Title: Journal of the American College of Cardiology
          Publisher: Elsevier BV
          ISSN (Electronic): 1558-3597
          ISSN (Print): 0735-1097
          Publication date (Electronic): Jun 14 2016
          Volume: 67
          Issue: 23
          Affiliations
          [1 ] TIMI Study Group, Brigham and Women's Hospital Heart & Vascular Center, Boston, Massachusetts. Electronic address: mbonaca@partners.org.
          [2 ] TIMI Study Group, Brigham and Women's Hospital Heart & Vascular Center, Boston, Massachusetts.
          [3 ] Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom.
          [4 ] French Alliance for Cardiovascular Trials, Université Paris-Diderot, Paris, France.
          [5 ] Cardiovascular Division, Newark Beth Israel Medical Center, Icahn School of Medicine at Mount Sinai, New York, New York.
          [6 ] Heart Institute (InCor)-University of São Paulo Medical School, São Paulo, Brazil.
          [7 ] Ukranian Strazhesko Institute of Cardiology, Kiev, Ukraine.
          [8 ] Hospital Universitario La Paz, Instituto de Investigación La Paz, Madrid, Spain.
          [9 ] Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
          [10 ] Life Fourways Hospital, Randburg, South Africa.
          [11 ] University Hospital, Jihlavska, Brno, Czech Republic.
          [12 ] Division of Medicine, Cardiac & Critical Care Services, Flinders Medical Centre, South Australia, Australia.
          [13 ] Cardiovascular Division, Pontificia Universidad Católica de Chile, Santiago, Chile.
          [14 ] Philippine Heart Center, University of the Philippines College of Medicine, Manila, Philippines.
          [15 ] AstraZeneca R&D, Mölndal, Sweden.
          Article
          Publisher Item ID: S0735-1097(16)32403-2
          DOI: 10.1016/j.jacc.2016.03.524
          PubMed ID: 27046162
          SO-VID: 35deed3e-7a32-4e25-b4a0-56fd49e1844c
          History

          Keywords: major adverse limb events,major adverse cardiovascular events,peripheral arterial disease,ticagrelor,acute limb ischemia
          Data availability:
          Keywords: major adverse limb events, major adverse cardiovascular events, peripheral arterial disease, ticagrelor, acute limb ischemia

          Comments

          Comment on this article